Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06821061 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
A Phase 1 study of Influenza and COVID-19 (Coronavirus Disease 2019), sponsored by BioNTech SE.
- Completed
- Registry status
- Phase 1
- Development phase
- 2,650
- Enrollment target
- 20
- Study locations
NCT06821061 is a Phase 1 study of Influenza and COVID-19 (Coronavirus Disease 2019) that has completed, run by BioNTech SE. The registered enrollment target is 2,650 participants, below the 36,787-participant average among 156 other Influenza trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06821061, a Phase 1 study of Influenza and COVID-19 (Coronavirus Disease 2019), has completed, sponsored by BioNTech SE.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2,650 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Conditions Studied
Interventions
- BIOLOGICAL Investigational Influenza Vaccine
- BIOLOGICAL Investigational COVID-19 Vaccine
- COMBINATION_PRODUCT Investigational Influenza and COVID-19 Combination Vaccine
- BIOLOGICAL Licensed Influenza Vaccine 1
- BIOLOGICAL Licensed Influenza Vaccine 2
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- Orange County Research Center - Lake Forest
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- Alliance for Multispecialty Research, LLC - Doral
- Indago Research & Health Center, Inc - Hialeah
- Miami Dade Medical Research Institute, LLC - Miami
- Palm Springs Community Health Center - Miami Lakes
New York
- Upstate Global Health Institute - East Syracuse
- University of Rochester Medical Center - Rochester
Connecticut
- Clinical Research Consulting - Milford
Georgia
- Clinical Research Atlanta - Stockbridge
Hawaii
- East-West Medical Research Institute - Honolulu
Missouri
- Clinical Research Professionals - Chesterfield
Nevada
- Las Vegas Clinical Trials - North Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,650 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2025-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06821061
The ClinicalTrials.gov registry entry for NCT06821061 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2,650 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,787-participant average among 156 other Influenza trials with a reported enrollment target (93% lower). The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Influenza appearing as the primary indexed condition, and to 5 interventions - of which Investigational Influenza Vaccine is the first listed.
NCT06821061 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06821061 about?
NCT06821061 is a clinical study titled "A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People". The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. P...
What is the current status of trial NCT06821061?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2,650 participants. The study started on 2025-02-10. Estimated completion is 2025-12-17.
What conditions does trial NCT06821061 study?
This clinical trial studies the following conditions: Influenza, COVID-19 (Coronavirus Disease 2019).
What interventions are being tested in trial NCT06821061?
The interventions under investigation include: Investigational Influenza Vaccine (BIOLOGICAL), Investigational COVID-19 Vaccine (BIOLOGICAL), Investigational Influenza and COVID-19 Combination Vaccine (COMBINATION_PRODUCT), Licensed Influenza Vaccine 1 (BIOLOGICAL), Licensed Influenza Vaccine 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06821061?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06821061 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.